| Levonordefrin | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
| Levonordefrin | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | |
| Levonordefrin | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | |
| Levonordefrin | hsa00630 | Glyoxylate and dicarboxylate metabolism | 2.48E-02 | 2 | P40926, P15104 | MDH2, GLUL | More | |
| Levonordefrin | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
| Levonordefrin | hsa00830 | Retinol metabolism | 4.25E-02 | 1 | P00325 | ADH1B | More | |
| Levonordefrin | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
| Levonordefrin | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Levonordefrin | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | |
| Levonordefrin | hsa03010 | Ribosome | 1.53E-05 | 8 | P62753, P62906, P46776, Q07020, P61513, P27635, P62249, P23396 | RPS6, RPL10A, RPL27A, RPL18, RPL37A, RPL10, RPS16, RPS3 | More | |
| Levonordefrin | hsa03015 | mRNA surveillance pathway | 1.83E-02 | 3 | Q13362, Q14738, Q9UBU9 | PPP2R5C, PPP2R5D, NXF1 | More | |
| Levonordefrin | hsa03040 | Spliceosome | 1.46E-02 | 4 | P17844, P51991, P61978, P11142 | DDX5, HNRPA3, HNRPK, HSPA8 | More | |
| Levonordefrin | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04012 | ErbB signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04014 | Ras signaling pathway | 3.65E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04015 | Rap1 signaling pathway | 2.99E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04022 | cGMP-PKG signaling pathway | 3.15E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04024 | cAMP signaling pathway | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04062 | Chemokine signaling pathway | 3.98E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04071 | Sphingolipid signaling pathway | 3.35E-03 | 5 | P04049, P21453, Q9H228, P01375, Q13362 | RAF1, S1PR1, EDG8, TNF, PPP2R5C | More | |
| Levonordefrin | hsa04072 | Phospholipase D signaling pathway | 2.82E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
| Levonordefrin | hsa04114 | Oocyte meiosis | 3.65E-02 | 3 | P0DP23, Q13362, Q14738 | CALM1, PPP2R5C, PPP2R5D | More | |
| Levonordefrin | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
| Levonordefrin | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04141 | Protein processing in endoplasmic reticulum | 2.82E-04 | 8 | P18848, Q15437, Q15436, Q99941, P11142, P07900, Q9NR31, P14625 | ATF4, SEC23B, SEC23A, CREBL1, HSPA8, HSP90AA1, SAR1A, HSP90B1 | More | |
| Levonordefrin | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04151 | PI3K-Akt signaling pathway | 4.12E-04 | 9 | P62753, P27348, P07900, P14625, Q16363, P22105, Q99941, P18848, O00141 | RPS6, YWHAQ, HSP90AA1, HSP90B1, LAMA4, TNXB, CREBL1, ATF4, SGK | More | |
| Levonordefrin | hsa04152 | AMPK signaling pathway | 1.83E-02 | 3 | Q96RR4, Q13362, Q14738 | CAMKK2, PPP2R5C, PPP2R5D | More | |
| Levonordefrin | hsa04210 | Apoptosis | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04211 | Longevity regulating pathway | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | |
| Levonordefrin | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | |
| Levonordefrin | hsa04218 | Cellular senescence | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04261 | Adrenergic signaling in cardiomyocytes | 1.73E-04 | 9 | P07550, P51828, P22694, Q99941, P18848, Q13362, Q14738, P0DP23, Q13557 | ADRB2, ADCY7, PRKACB, CREBL1, ATF4, PPP2R5C, PPP2R5D, CALM1, CAMK2D | More | |
| Levonordefrin | hsa04270 | Vascular smooth muscle contraction | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04360 | Axon guidance | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04370 | VEGF signaling pathway | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04371 | Apelin signaling pathway | 2.65E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04540 | Gap junction | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | |
| Levonordefrin | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
| Levonordefrin | hsa04613 | Neutrophil extracellular trap formation | 2.65E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04625 | C-type lectin receptor signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04630 | JAK-STAT signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04650 | Natural killer cell mediated cytotoxicity | 2.93E-05 | 8 | P01375, P20963, P04049, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, RAF1, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
| Levonordefrin | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | |
| Levonordefrin | hsa04660 | T cell receptor signaling pathway | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04662 | B cell receptor signaling pathway | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04664 | Fc epsilon RI signaling pathway | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04666 | Fc gamma R-mediated phagocytosis | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
| Levonordefrin | hsa04714 | Thermogenesis | 3.31E-02 | 4 | P51828, P62753, P12074, O15239 | ADCY7, RPS6, COX6A1, NDUFA1 | More | |
| Levonordefrin | hsa04720 | Long-term potentiation | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04722 | Neurotrophin signaling pathway | 7.10E-03 | 4 | P04049, P49841, O43524, P48023 | RAF1, GSK3B, FOXO3, FASLG | More | |
| Levonordefrin | hsa04725 | Cholinergic synapse | 2.17E-02 | 3 | P51828, P18848, Q13557 | ADCY7, ATF4, CAMK2D | More | |
| Levonordefrin | hsa04726 | Serotonergic synapse | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04728 | Dopaminergic synapse | 3.20E-03 | 6 | Q99941, P18848, Q13557, Q13362, Q14738, P0DP23 | CREBL1, ATF4, CAMK2D, PPP2R5C, PPP2R5D, CALM1 | More | |
| Levonordefrin | hsa04730 | Long-term depression | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | |
| Levonordefrin | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
| Levonordefrin | hsa04810 | Regulation of actin cytoskeleton | 3.81E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04910 | Insulin signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04911 | Insulin secretion | 4.03E-04 | 4 | P51828, Q99941, P18848, Q13557 | ADCY7, CREBL1, ATF4, CAMK2D | More | |
| Levonordefrin | hsa04912 | GnRH signaling pathway | 3.36E-03 | 4 | P51828, P18848, Q13557, P04049 | ADCY7, ATF4, CAMK2D, RAF1 | More | |
| Levonordefrin | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
| Levonordefrin | hsa04914 | Progesterone-mediated oocyte maturation | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04915 | Estrogen signaling pathway | 4.99E-04 | 6 | P04049, Q99941, P18848, P51828, P07900, P11142 | RAF1, CREBL1, ATF4, ADCY7, HSP90AA1, HSPA8 | More | |
| Levonordefrin | hsa04916 | Melanogenesis | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04917 | Prolactin signaling pathway | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04918 | Thyroid hormone synthesis | 1.98E-04 | 5 | P51828, Q99941, P18848, P14625, P02768 | ADCY7, CREBL1, ATF4, HSP90B1, ALB | More | |
| Levonordefrin | hsa04919 | Thyroid hormone signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04921 | Oxytocin signaling pathway | 4.61E-03 | 4 | P0DP23, P04049, Q96RR4, Q13469 | CALM1, RAF1, CAMKK2, NFATC2 | More | |
| Levonordefrin | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
| Levonordefrin | hsa04925 | Aldosterone synthesis and secretion | 1.69E-03 | 4 | Q99941, P18848, P51828, Q13557 | CREBL1, ATF4, ADCY7, CAMK2D | More | |
| Levonordefrin | hsa04926 | Relaxin signaling pathway | 5.73E-04 | 7 | Q99941, P18848, P22694, P14780, P51828, P04049, P30679 | CREBL1, ATF4, PRKACB, MMP9, ADCY7, RAF1, GNA15 | More | |
| Levonordefrin | hsa04927 | Cortisol synthesis and secretion | 2.72E-04 | 4 | Q99941, P18848, P51828, P22694 | CREBL1, ATF4, ADCY7, PRKACB | More | |
| Levonordefrin | hsa04928 | Parathyroid hormone synthesis, secretion and action | 3.95E-03 | 4 | P51828, P04049, Q99941, P18848 | ADCY7, RAF1, CREBL1, ATF4 | More | |
| Levonordefrin | hsa04929 | GnRH secretion | 4.98E-03 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa04932 | Non-alcoholic fatty liver disease | 2.74E-02 | 3 | P01375, P49841, P48023 | TNF, GSK3B, FASLG | More | |
| Levonordefrin | hsa04934 | Cushing syndrome | 1.12E-03 | 4 | Q99941, P18848, P51828, Q13557 | CREBL1, ATF4, ADCY7, CAMK2D | More | |
| Levonordefrin | hsa04935 | Growth hormone synthesis, secretion and action | 5.33E-03 | 4 | P51828, P04049, Q99941, P18848 | ADCY7, RAF1, CREBL1, ATF4 | More | |
| Levonordefrin | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Levonordefrin | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Levonordefrin | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Levonordefrin | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
| Levonordefrin | hsa04979 | Cholesterol metabolism | 1.61E-02 | 2 | P38571, P61916 | LIPA, NPC2 | More | |
| Levonordefrin | hsa05030 | Cocaine addiction | 4.87E-02 | 2 | Q99941, P18848 | CREBL1, ATF4 | More | |
| Levonordefrin | hsa05031 | Amphetamine addiction | 8.84E-04 | 5 | Q13557, P22694, Q99941, P18848, Q13547 | CAMK2D, PRKACB, CREBL1, ATF4, HDAC1 | More | |
| Levonordefrin | hsa05034 | Alcoholism | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05132 | Salmonella infection | 4.98E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | |
| Levonordefrin | hsa05143 | African trypanosomiasis | 7.50E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | |
| Levonordefrin | hsa05144 | Malaria | 1.44E-03 | 5 | P69905, P68871, P01375, P35443, P26718 | HBA2, HBB, TNF, THBS4, KLRK1 | More | |
| Levonordefrin | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
| Levonordefrin | hsa05152 | Tuberculosis | 3.98E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05160 | Hepatitis C | 1.40E-03 | 5 | P60033, P04049, P49841, P01375, P48023 | CD81, RAF1, GSK3B, TNF, FASLG | More | |
| Levonordefrin | hsa05161 | Hepatitis B | 5.33E-03 | 4 | P04049, Q99941, P18848, P27348 | RAF1, CREBL1, ATF4, YWHAQ | More | |
| Levonordefrin | hsa05163 | Human cytomegalovirus infection | 4.98E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05164 | Influenza A | 3.65E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.06E-02 | 4 | P23458, Q13469, P04049, P0DP23 | JAK1, NFATC2, RAF1, CALM1 | More | |
| Levonordefrin | hsa05170 | Human immunodeficiency virus 1 infection | 3.48E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05171 | Coronavirus disease - COVID-19 | 4.36E-05 | 8 | P23396, P62753, P62249, P62906, P27635, Q07020, P46776, P61513 | RPS3, RPS6, RPS16, RPL10A, RPL10, RPL18, RPL27A, RPL37A | More | |
| Levonordefrin | hsa05203 | Viral carcinogenesis | 1.46E-02 | 4 | Q99941, P18848, P27348, P61978 | CREBL1, ATF4, YWHAQ, HNRPK | More | |
| Levonordefrin | hsa05205 | Proteoglycans in cancer | 1.09E-02 | 6 | P04049, P14780, P01375, P23588, Q13635, P22694 | RAF1, MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
| Levonordefrin | hsa05206 | MicroRNAs in cancer | 3.15E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05210 | Colorectal cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05211 | Renal cell carcinoma | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05212 | Pancreatic cancer | 4.13E-03 | 3 | P04049, Q15311, P23458 | RAF1, RALBP1, JAK1 | More | |
| Levonordefrin | hsa05213 | Endometrial cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05214 | Glioma | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05215 | Prostate cancer | 3.72E-03 | 3 | P18848, P14625, P04049 | ATF4, HSP90B1, RAF1 | More | |
| Levonordefrin | hsa05218 | Melanoma | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05219 | Bladder cancer | 4.98E-03 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05220 | Chronic myeloid leukemia | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05221 | Acute myeloid leukemia | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05223 | Non-small cell lung cancer | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05224 | Breast cancer | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05226 | Gastric cancer | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05230 | Central carbon metabolism in cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05231 | Choline metabolism in cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Levonordefrin | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
| Levonordefrin | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Levonordefrin | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | |
| Levonordefrin | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | |
